リハビリテーションの適用と肺高血圧管理の進展
Yuyan Liu1,2, Xiao Guo1,2, Panpan Liu3
1Rehabilitation Medicine College, Shandong Second Medical University, Weifang, China.
Frontiers in medicine
|September 2, 2025
まとめ
肺高血圧のリハビリテーション療法は,運動能力と生活の質を改善します. この非薬学的なアプローチは,肺高血圧 (PH) の患者の身体的および心理的な健康を改善します.
科学分野:
- 心臓病と呼吸器医学
- リハビリテーション科学
背景:
- 肺高血圧 (PH) は運動耐性と生活の質を著しく低下させる.
- 薬学的治療は症状を和らげますが,機能的制限を完全に解決しません.
- リハビリテーション療法はPH管理のための重要な非薬学的介入として登場します.
研究 の 目的:
- 肺高血圧管理におけるリハビリテーション療法の役割と進歩をレビューする.
- リハビリテーションの効果と 患者の生活の質の改善を強調する
- PHリハビリテーションの将来の方向性を探す
主な方法:
- 臨床的特徴,流行,およびPHの治療に関する包括的なレビュー.
- 様々なリハビリテーション方法に重点を置く:運動トレーニング,鼓動筋トレーニング,神経筋肉の電気刺激,心理的なサポート.
- リハビリテーションの安全性と有効性に関する新たな証拠の分析
主要な成果:
- リハビリテーション療法は,PH患者の心肺機能,筋肉の強さ,運動能力の改善に安全で効果的です.
- 呼吸不全,不安,うつといった 重要な症状を緩和します
- 生活の質の向上と社会的な役割への再統合が観察されています.
結論:
- リハビリテーション療法は,肺高血圧の患者に大きな利点をもたらします.
- 身体的,心理的,社会的機能を改善することで 薬理学的アプローチを補完します
- リハビリテーションを通じてPH管理を最適化するためにさらなる研究と革新的なアプローチが必要である.
関連する概念動画
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
251
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
251
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
317
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
317
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
253
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
253
Pulmonary Hypertension: Classification and Pathogenesis
284
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
284
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
223
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
223
Chronic Obstructive Pulmonary Disease-V: Management
2.7K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.7K


